Related Experiment Video

Updated: Jun 22, 2026

A Protocol for Analyzing Hepatitis C Virus Replication
13:04

A Protocol for Analyzing Hepatitis C Virus Replication

Published on: June 26, 2014

Chronic hepatitis C in patients co-infected with human immunodeficiency virus in Japan: a retrospective multicenter

Hiroshi Yotsuyanagi1, Yoshimi Kikuchi, Kunihisa Tsukada

  • 1Department of Internal Medicine, Graduate School of Medicine, University of Tokyo, Tokyo, Japan.

Hepatology Research : the Official Journal of the Japan Society of Hepatology
|May 29, 2009
PubMed

Insights

Nearly one-fifth of human immunodeficiency virus (HIV)-positive patients have hepatitis C virus (HCV) co-infection. Advanced liver disease is common in these patients, but interferon treatment may slow its progression.

Area of Science:

  • Hepatology
  • Virology
  • Immunology

Background:

  • A significant proportion of human immunodeficiency virus (HIV)-positive individuals in Japan are co-infected with hepatitis C virus (HCV).
  • Understanding the specific features of liver disease in HIV-HCV co-infected patients is crucial for effective management.

Purpose of the Study:

  • To analyze the characteristics of liver disease in patients with HIV-HCV co-infection.
  • To evaluate the impact of interferon treatment on liver disease progression in this population.

Main Methods:

  • A study involving 297 patients from eight hospitals within the HIV/AIDS Network of Japan.
  • Analysis of HCV genotypes, liver disease advancement, and response to interferon treatment.

Main Results:

  • HCV genotypes other than 1 and 2 were prevalent in co-infected patients, suggesting transmission via contaminated blood products.
  • Sixteen patients presented with advanced liver disease at a younger age compared to HCV mono-infected patients.
  • Interferon treatment led to a 43.3% sustained virological response rate and appeared to slow liver disease progression.

Conclusions:

  • HIV-HCV co-infected patients exhibit more advanced liver disease than those with HCV mono-infection.
  • Interferon therapy shows promise in retarding liver disease progression in HIV-HCV co-infected individuals.
Abstract

Related Concept Videos

Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Viral Hepatitis I: Introduction01:28

Viral Hepatitis I: Introduction

Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...
Cytomegalovirus Disease01:27

Cytomegalovirus Disease

Cytomegalovirus (CMV) disease is caused by human cytomegalovirus, a double-stranded DNA virus of the Herpesviridae family. While primary CMV infection is often asymptomatic in immunocompetent individuals, the virus can cause severe disease in neonates and immunocompromised patients. CMV is the most common cause of congenital viral infection in the United States, and a major pathogen in solid organ and hematopoietic stem cell transplant recipients.CMV is transmitted via bodily fluids, sexual...
Chronic Pancreatitis II: Collaborative Care01:29

Chronic Pancreatitis II: Collaborative Care

The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
Diseases of the Liver and Gallbladder01:26

Diseases of the Liver and Gallbladder

Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not related to...
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...